Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

Dhan Chand, David A. Savitsky, Shanmugarajan Krishnan, Gabriel Mednick, Chloe Delepine, Pilar Garcia-Broncano, Kah Teong Soh, Wei Wu, Margaret K. Wilkens, Olga Udartseva, Sylvia Vincent, Bishnu Joshi, Justin G. Keith, Mariana Manrique, Marilyn Marques, Antoine Tanne, Daniel L. Levey, Haiyong Han, Serina Ng, Jackson Ridpath, Olivia Huber, Benjamin Morin, Claire Galand, Sean Bourdelais, Randi B. Gombos, Rebecca Ward, Yu Qin, Jeremy D. Waight, Matthew R. Costa, Alvaro Sebastian-Yague, Nils-Petter Rudqvist, Malgorzata Pupecka-Swider, Vignesh Venkatraman, Andrew Slee, Jaymin M. Patel, Joseph E. Grossman, Nicholas S. Wilson, Daniel D. Von Hoff, Justin Stebbing, Tyler J. Curiel, Jennifer S. Buell, Steven J. O’Day, Robert B. Stein

Open source

DOI: 10.1158/2159-8290.cd-24-0190
Published: 2024-07-31
Container: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/2159-8290.cd-24-0190,
  title = {Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy},
  author = {Dhan Chand and David A. Savitsky and Shanmugarajan Krishnan and Gabriel Mednick and Chloe Delepine and Pilar Garcia-Broncano and Kah Teong Soh and Wei Wu and Margaret K. Wilkens and Olga Udartseva and Sylvia Vincent and Bishnu Joshi and Justin G. Keith and Mariana Manrique and Marilyn Marques and Antoine Tanne and Daniel L. Levey and Haiyong Han and Serina Ng and Jackson Ridpath and Olivia Huber and Benjamin Morin and Claire Galand and Sean Bourdelais and Randi B. Gombos and Rebecca Ward and Yu Qin and Jeremy D. Waight and Matthew R. Costa and Alvaro Sebastian-Yague and Nils-Petter Rudqvist and Malgorzata Pupecka-Swider and Vignesh Venkatraman and Andrew Slee and Jaymin M. Patel and Joseph E. Grossman and Nicholas S. Wilson and Daniel D. Von Hoff and Justin Stebbing and Tyler J. Curiel and Jennifer S. Buell and Steven J. O’Day and Robert B. Stein},
  year = {2024},
  journal = {Cancer Discovery},
  doi = {10.1158/2159-8290.cd-24-0190},
  url = {https://doi.org/10.1158/2159-8290.cd-24-0190}
}

RIS

TY  - JOUR
TI  - Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
AU  - Dhan Chand
AU  - David A. Savitsky
AU  - Shanmugarajan Krishnan
AU  - Gabriel Mednick
AU  - Chloe Delepine
AU  - Pilar Garcia-Broncano
AU  - Kah Teong Soh
AU  - Wei Wu
AU  - Margaret K. Wilkens
AU  - Olga Udartseva
AU  - Sylvia Vincent
AU  - Bishnu Joshi
AU  - Justin G. Keith
AU  - Mariana Manrique
AU  - Marilyn Marques
AU  - Antoine Tanne
AU  - Daniel L. Levey
AU  - Haiyong Han
AU  - Serina Ng
AU  - Jackson Ridpath
AU  - Olivia Huber
AU  - Benjamin Morin
AU  - Claire Galand
AU  - Sean Bourdelais
AU  - Randi B. Gombos
AU  - Rebecca Ward
AU  - Yu Qin
AU  - Jeremy D. Waight
AU  - Matthew R. Costa
AU  - Alvaro Sebastian-Yague
AU  - Nils-Petter Rudqvist
AU  - Malgorzata Pupecka-Swider
AU  - Vignesh Venkatraman
AU  - Andrew Slee
AU  - Jaymin M. Patel
AU  - Joseph E. Grossman
AU  - Nicholas S. Wilson
AU  - Daniel D. Von Hoff
AU  - Justin Stebbing
AU  - Tyler J. Curiel
AU  - Jennifer S. Buell
AU  - Steven J. O’Day
AU  - Robert B. Stein
PY  - 2024
JO  - Cancer Discovery
DO  - 10.1158/2159-8290.cd-24-0190
UR  - https://doi.org/10.1158/2159-8290.cd-24-0190
ER  -

APA

Chand, D., Savitsky, D. A., Krishnan, S., Mednick, G., Delepine, C., Garcia-Broncano, P., Soh, K. T., Wu, W., Wilkens, M. K., Udartseva, O., Vincent, S., Joshi, B., Keith, J. G., Manrique, M., Marques, M., Tanne, A., Levey, D. L., Han, H., Ng, S., Ridpath, J., Huber, O., Morin, B., Galand, C., Bourdelais, S., Gombos, R. B., Ward, R., Qin, Y., Waight, J. D., Costa, M. R., Sebastian-Yague, A., Rudqvist, N., Pupecka-Swider, M., Venkatraman, V., Slee, A., Patel, J. M., Grossman, J. E., Wilson, N. S., Hoff, D. D. V., Stebbing, J., Curiel, T. J., Buell, J. S., O’Day, S. J., & Stein, R. B. (2024). Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-24-0190

Source records

crossref · retrieved 2026-09-26T22:34:46.470Z